Xaluprine® 20 mg/ml

Xaluprine® is a liquid formulation of mercaptopurine for the treatment of acute lymphoblastic leukemia (ALL) in children. The EMA-approved formulation enables accurate, age- and weight-specific dosing. This addresses a significant medical need in this rare and serious disease. Xaluprine® received orphan drug status in 2012 for this child-friendly liquid dosage form.

Learn more about Xaluprine®

For detailed information about Xaluprine®, please visit our official website: www.xaluprine.info. There you will find comprehensive medical and multilingual information.